osteolabs GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
osteolabs GmbH - overview
Established
2018
Location
Kiel, -, Germany
Primary Industry
Medical Devices & Equipment
About
osteolabs GmbH is a German company specializing in advanced biomarker technology for precise bone density measurement, primarily focusing on early risk assessment of metabolic bone diseases. Founded in 2018 and headquartered in Kiel, Germany, osteolabs GmbH develops innovative diagnostic solutions in the field of bone health. The firm was established by Anton Eisenhauer and Rndr. Kloth, with Michael Lutz serving as CEO.
In June 2019, the company secured SEED funding to enhance its operations. The core offering of osteolabs GmbH is the CIM biomarker technology, enabling accurate measurement of changes in bone density. This product aids in assessing metabolic bone diseases such as osteoporosis and serves various clientele including hospitals and research institutions across Europe and North America. The company collaborates with organizations like the German Sport University Cologne to tailor their diagnostics to the athletic community.
Revenue for osteolabs GmbH is generated through the sale of CIM biomarker technology to healthcare providers and research institutions, which includes bulk kit purchases and licensing agreements. The revenue model emphasizes sustained engagement with clients through ongoing diagnostic services and updates, focusing on the growing demand for bone health management tools. Following the SEED funding in June 2019 from Laboratory Dr. Krause & Kollegen MVZ GmbH, MBG Baden-Wurttemberg, and other investors, osteolabs GmbH plans to develop new products targeting advanced diagnostics in bone health.
The company aims to expand its market presence in North America and Europe by 2023, leveraging funding to enhance product development and increase sales capabilities.
Current Investors
MBG Baden-Wuerttemberg, Laboratory Dr. Krause & Kollegen MVZ GmbH
Primary Industry
Medical Devices & Equipment
Sub Industries
Monitoring Equipment, Medical Supplies, Diagnostic Equipment
Website
www.osteolabs.de
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
osteolabs GmbH - financials
| Fiscal Year Ended | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
osteolabs GmbH - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.